Skip to main content
Clinical Trials/CTRI/2018/01/011309
CTRI/2018/01/011309
Not yet recruiting
未知

A randomised, double blinded, comparative study to investigate the effectiveness & safety of Me-Cal in osteoporosis patients as compared to standard calcium supplement containing calcitrol, calcium and zinc.

SG PHYTO PHARMA PVT LTD0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- OSTEOPOROSIS
Sponsor
SG PHYTO PHARMA PVT LTD
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
SG PHYTO PHARMA PVT LTD

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients complaining of classical symptoms of
  • joint pain, pain in the bones etc. which will
  • be confirmed later by the BMD\-test with BMD
  • score below \-1\.
  • 2\. Patient agrees not to use any other calcium
  • supplement for osteoporosis other than what is
  • provided by the study.
  • 3\. Patient agrees to written informed consent.
  • 4\. Patient willing to participate in the study
  • for 12 weeks.

Exclusion Criteria

  • 1\.Planning to conceive, pregnant and lactating mothers.
  • 2\. Patient under osteoporosis treatment.
  • 3\. Patients suffering from heart disease.
  • 4\. Patients with severe renal impairment.
  • 5\. Patient with known metabolic bone disease such
  • as osteogenesis imperfecta, or currently
  • healing fractures of lumbar spine, hips or
  • 6\. Patient on current treatment with steroids or
  • chemotherapy.
  • 7\. History of malignancy

Outcomes

Primary Outcomes

Not specified

Similar Trials